Expertise in
1
conditions

Sharlaa Faesen-Badal

Johannesburg, GT, ZA 
Expertise in
1
conditions
Johannesburg, GT, ZA 

Overview

Sharlaa Faesen-Badal practices practicing medicine in Johannesburg, South Africa.

Faesen-Badal is highly rated in 1 condition, according to our data. Their clinical expertise encompasses HIV/AIDS, Pulmonary Tuberculosis, and Kaposi Sarcoma.

They are actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 2 clinical trials.

Locations

Johannesburg, GT, South Africa
Other Locations
South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or With Rifampin-Containing TB Treatment: The Hakim Study
Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or With Rifampin-Containing TB Treatment: The Hakim Study
Enrollment Status: Completed
Publish Date: August 21, 2023
Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)
Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)
Enrollment Status: Completed
Publish Date: August 01, 2022
Intervention Type: Biological
Study Drug: Ad26.COV2.S COVID-19 vaccine
Study Phase: Phase 3
View 1 Less Clinical Trial

42 Total Publications

Islatravir distribution in plasma, peripheral blood mononuclear cells, and mucosal tissues after monthly oral dosing.
Islatravir distribution in plasma, peripheral blood mononuclear cells, and mucosal tissues after monthly oral dosing.
Journal: AIDS (London, England)
Published: November 03, 2025

Frequently Asked Questions about Sharlaa Faesen-Badal

Is Sharlaa Faesen-Badal a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Sharlaa Faesen-Badal is classified as an Advanced expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sharlaa Faesen-Badal participate in research or clinical trials?

Yes. Sharlaa Faesen-Badal has published 42 articles and abstracts on conditions like HIV/AIDS. You can view a list of Sharlaa Faesen-Badal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Faesen-Badal's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile